Neubauer, A., Wiesmann, T., Vogelmeier, C. F., Mack, E., Skevaki, C., Gaik, C., . . . Burchert, A. (2020). Ruxolitinib for the treatment of SARS-CoV-2 induced acute respiratory distress syndrome (ARDS). Leukemia.
Παραπομπή Chicago StyleNeubauer, Andreas, et al. "Ruxolitinib for the Treatment of SARS-CoV-2 Induced Acute Respiratory Distress Syndrome (ARDS)." Leukemia 2020.
Παραπομπή MLANeubauer, Andreas, et al. "Ruxolitinib for the Treatment of SARS-CoV-2 Induced Acute Respiratory Distress Syndrome (ARDS)." Leukemia 2020.
Πρόσοχή: Οι παραπομπές μπορεί να μην είναι 100% ακριβείς.